Scholarlink

<p>HIV drug resistance (HIVDR) was retrospectively characterized among 20 children and adolescents with HIV with virologic failure on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, and virologic response in those switched to dolutegravir (DTG)-based therapy described. All participants had at least one NNRTI resistance mutation, most commonly K103N (<i>N</i> = 12) and 15 (75%) had nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, most commonly M184I/V (<i>N</i> = 15). Five (45%) of 11 participants who were switched to DTG-based regimens for a median of 50 months had HIV suppression. Further studies to understand the role of pre-existing HIVDR in the failure of DTG-based regimens are needed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HIV drug resistance in children and adolescents on NNRTI-based antiretroviral therapy and subsequent virologic response to dolutegravir-based regimens in Ghana

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月26日

查看全文
  • Adwoa K.A Afrane,
  • Vlad Novitsky,
  • Joel Hague,
  • Kwamena Sagoe,
  • Yakubu Alhassan,
  • Joycelyn Assimeng Dame,
  • Charles Martyn-Dickens,
  • Margaret Lartey,
  • Bamenla Goka,
  • Kwasi Torpey,
  • Rami Kantor,
  • Awewura Kwara

摘要

HIV drug resistance (HIVDR) was retrospectively characterized among 20 children and adolescents with HIV with virologic failure on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy, and virologic response in those switched to dolutegravir (DTG)-based therapy described. All participants had at least one NNRTI resistance mutation, most commonly K103N (N = 12) and 15 (75%) had nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, most commonly M184I/V (N = 15). Five (45%) of 11 participants who were switched to DTG-based regimens for a median of 50 months had HIV suppression. Further studies to understand the role of pre-existing HIVDR in the failure of DTG-based regimens are needed.